｜Edited by the Content Team of Zhong肽 BiochemicalSeptember 7, 2023Elicio Therapeutics announced that it has received a $2.6 million grant from the Chicago GI Research Foundation to fund research on two therapeutic cancer vaccines, ELI-007 and ELI-008. This $2.6 million grant supplements the $2.8 million awarded to Elicio in September 2022. The funds will be used to advance research on the mutant BRF peptide vaccine ELI-007 and the p53 hotspot mutant peptide vaccine ELI-008, with the aim of developing multivalent cancer vaccines targeting various mutations. Both vaccines are designed using Elicio's proprietary lymph node-targeting amphiphile (AMP) platform, which "educates" T cells on how to target specific antigens, such as mutated proteins in cancer.
Elicio Achieves Several Key Milestones in the Development of These Two Vaccines:amp - Verification of the feasibility of vaccine design and production, validation of robust in vivo immunogenicity, and execution of CMC, IND regulatory and clinical strategic planning. This additional funding will help complete all manufacturing, regulatory, and clinical preparations required for ELI-007 and ELI-008 to move forward. The grant will enable Elicio to conduct initial patient clinical evaluations.Christopher Haqq, MD, Executive Vice President, Head of R&D, and Chief Medical Officer of Elicio, added: "This is another significant milestone for the company in what has been an exciting year. We have publicly announced the initial positive Phase 1 data for our lead cancer vaccine candidate, ELI-002, in mKRAS-driven tumors. The AMP platform is an ideal vehicle for cancer vaccine development because it allows us to leverage the lymph nodes as the immune system's 'schoolhouse,' educating T cells on how to recognize and eliminate these aggressive cancers. We are honored to collaborate with the GI Research Foundation to provide additional potential tools for treating BRAF and p53 mutant cancers."About Amphiphile Platform
Our proprietary Amphiphile (AMP) platform delivers experimental immunotherapies directly to the "brain center" of the immune system—the lymph nodes. We believe that this site-specific delivery of disease-specific antigens, adjuvants, and other immunomodulators may effectively educate, activate, and amplify critical immune cells, potentially inducing and sustaining effective adaptive immunity, which is essential for treating many diseases. In preclinical models, we have observed that lymph node-specific engagement enhances the intensity, functionality, and durability of therapeutic immune responses.
About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is designing investigational Amphiphile (AMP) immunotherapies intended to precisely target and fully engage the lymph nodes, which are the sites in our body that orchestrate immune responses. Elicio is engineering lymph node-targeted amplifiers, immune modulators, adjuvants, and vaccines for a range of aggressive cancers.
Source:
1.Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines - Elicio Therapeutics Inc.
